Dei BioPharma Ltd, the company developing the multi-billion-shilling drug and vaccine producing facility owned by Ugandan scientist Dr Matthias Magoola, has said the plant will start manufacturing essential antibiotic medicines and vaccines in October.
The facility is expected to produce both human and animal vaccines, Dr Magoola, told journalists on Thursday during an inspection by opposition figures including Leader of Opposition in Parliament (LoP) Joel Ssenyonyi.
“We are trying to import raw materials because the structure is in place and the manpower is available. We have experts who are ready to exhibit their knowledge in terms of manufacturing different vaccines,” Dr Magoola said after inspection at the facility's 150-acre campus in Matugga, Wakiso District central Uganda.
Dr Magoola also noted that the manufacturing plant consists of 10 different state-of-the-art components, each specializing in vaccines, generics, nutraceuticals, oncology/cancer, penicillin, cephalosporins, non-beta-lactam, injectables, WFI, parentals, medical devices, and ophthalmic products.
He added that the plant which also boasts of the vital YKTM GLP Biotech Laboratories, will cover the groundbreaking components of cancer research, drug discovery, gene therapy, cell therapy, mRNA therapeutics, vaccines, biosimilars, and biologics.
